Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant herpes zoster vaccine in adults 40+ years
NCT06932523Phase 2Recruiting
- Sponsor
- Shanghai Institute of Biological Products
- Start
- Apr 2025
- Primary completion
- Jun 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of recombinant herpes zoster vaccine (CHO cells) in herpes zoster (HZ) (10 arms), sponsored by Shanghai Institute of Biological Products. Primary endpoints: Immediate Adverse Events, Solicited Adverse Events at 14 days and 8 more. Started Apr 2025; status: recruiting.
02
Drugs
recombinant herpes zoster vaccine (CHO cells)
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT06932523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06932523.